CClinicalTrials.gg
CompletedNCT06681662Updated Sep 11, 2026

Ephedrine for Reducing Onset Time of Rocurinium in Elderly Patients

A Phase 4 interventional study of Ephedrine Hydrochloride 30 mg/ml and Saline (NaCl 0,9 %) (placebo) in Neuromuscular Blockade, sponsored by Matias Vested. Completed at 2 sites in Denmark. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Matias Vested · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
80 Years and older
Sex
All
01

Study summary

The aim of this study is to determine the onset time of rocuronium after administration of ephedrine 0.15 mg/kg in patients with age ≥ 80 years. The hypothesis of this study is that ephedrine 0.15 mg/kg provides a shorter onset time compared to placebo (saline).

Read the detailed description

Numbers of elderly patients requiring anesthesia and surgery are increasing, and as a group, elderly patients are at high risk of postoperative complications. Aging leads to a progressive impairment of organ function and a decline in physiologic reserve and in the elderly patient population, pharmacodynamics and pharmacokinetics of medications administered during anesthesia may be influenced by the age-related reduction in cardiac output, liver function and renal function. Also, the body composition changes with age and elderly have lower total body water and an increase in body fat.

Neuromuscular blocking agents (NMBAs) are administered during anesthesia to facilitate tracheal intubation. However, in elderly patients onset time of standard doses of NMBAs are prolonged, and for 0.6 mg/kg of rocuronium it is prolonged by 50% when comparing elderly with younger adults (median 135 seconds vs 90 seconds). A prolonged onset time of rocuronium may result in prolonged time to tracheal intubation which aims to secure the patients airway and breathing during anesthesia and thereby prevents pulmonary aspiration and hypoxia. It is therefore relevant to investigate measures to reduce onset time of rocuronium in the elderly.

Ephedrine administered in younger adults undergoing general anesthesia has reduced the onset time of rocuronium 0.6 mg/kg. The mechanism behind this is speculated to be an increase in cardiac output.

It is possible to detect onset time of NMBAs with objective neuromuscular monitoring perioperatively by train-of-four (TOF) stimulation at the ulnar nerve. The effect of ephedrine on onset time of rocuronium has not been assessed in elderly patients above 80 years of age.

The possible benefit of this trial is to investigate whether ephedrine 0.15 mg/kg reduces onset time of rocuronium 0.6 mg/kg in the elderly. This may result in a shorter time to tracheal intubation and also establish better intubating conditions. The results may help to detect the optimal method for administering rocuronium to facilitate tracheal intubation in elderly patients.

The investigators hypothesize that ephedrine 0.15 mg/kg will provide a shorter onset time of rocuronium compared to placebo (saline).

02

Conditions studied

  • Neuromuscular Blockade
03

In context

Lead sponsor

Matias Vested is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 80
  • Scheduled for elective operations under general anesthesia with intubation
  • American Society of Anesthesiologists physical status classification (ASA) I to III
  • Informed consent
  • Read and understand Danish

Exclusion criteria

Exclusion Criteria:

  • Known allergy to rocuronium or ephedrine
  • Neuromuscular disease that may interfere with neuromuscular data
  • Indication for rapid sequence induction
  • Daily use of beta-blocking agents
  • Known cardiac arrythmia (atrial fibrillation, supraventricular or ventricular)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Ephedrine group

    Ephedrine 0.15 mg/kg. Dose of ephedrine is based on ideal body weight, calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower.

    Drug: Ephedrine Hydrochloride 30 mg/ml

  • Placebo comparator
    Saline group

    Saline 1 ml.

    Drug: Saline (NaCl 0,9 %) (placebo)

Interventions

  • DrugEphedrine Hydrochloride 30 mg/ml

    0.15 mg/kg during induction.

  • DrugSaline (NaCl 0,9 %) (placebo)

    1 ml during induction.

06

What researchers measure

Primary outcomes

  1. Onset time of rocuronium 0.6 mg/kg defined as the time from administration of rocuronium until TOF count of 0.

    Onset time is determined by an investigator using a stop-watch.

    Time frame: Within 1 hour

Secondary outcomes

  1. Intubating conditions assessed by The Intubation Difficulty Scale (IDS)

    Tracheal intubation will be performed when TOF count is zero. The anesthesiologist or nurse anesthetist will be interviewed after intubation by the investigator, who will note a score for each variable and the initials of the operator in the CRF. The intubating conditions will be classified with "Degree of Difficulty" according to the IDS scale, where an IDS score of 0 translates to "Easy", a score of 0 \< IDS ≤ 5 translates to "Slight Difficulty" and 5 \< IDS translates to "Moderate to Major Difficulty". Impossible intubation is defined by infinity (IDS = ∞ ).

    Time frame: Within 1 hour

  2. Intubating conditions assessed by Fuchs-Buder scale

    Tracheal intubation will be performed when TOF count is zero. The anesthesiologist or nurse anesthetist will be interviewed after intubation by the investigator, who will note a score for each variable and the initials of the operator in the CRF. All variables will be assessed as either excellent, good or poor. The intubating conditions will be classified as excellent if all qualities are excellent, good if all qualities are either excellent or good and poor if the presence of a single quality listed as poor.

    Time frame: Within 1 hour

  3. Occurrence of new cardiac arrythmia during induction of anaesthesia (<15 minutes after administration of ephedrine or saline)

    Time frame: Within 15 minutes

  4. Change in mean arterial blood pressure from before induction to immediately after intubation

    Time frame: Within 1 hour

  5. Time to TOF 0.9

    Time frame: Within 4 hours

Other outcomes

  1. Occurrence of hoarseness and sore throat 24 and 72 hours postoperatively

    After 24 hours patients are asked about hoarseness and sore throat. The patients who experience either or both will be called 3 days postoperatively again. These two variables are assessed using a numeric ranking scale.

    Time frame: Within 72 hours

07

Study locations

2 sites
  • Department of Anaesthesiology, Pain and Respiratory Support, Rigshospitalet Glostrup
    Copenhagen, 2100, Denmark
  • Department of Anesthesia, Centre of Head and Orthopedics, 6013 Rigshospitalet
    Copenhagen, 2100, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681662
Lead sponsor
Matias Vested
Responsible party
Matias Vested (Principal Investigator, Medical Doctor, PhD, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Nov 8, 2024
Start date
Jan 13, 2025
Primary completion
Oct 5, 2025
Completion
Oct 5, 2025
Last update
Sep 11, 2026

Study contacts

Matias Vested
study chair · Rigshospitalet, University of Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion